Paola Queirolo
Martin University(US)Associazione Italiana Di Oncologia Medica(IT)Istituti di Ricovero e Cura a Carattere Scientifico(IT)Alleanza Contro il Cancro(IT)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study(2013)639 cited
- → Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial(2020)513 cited
- → Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study(2010)509 cited
- → Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial(2017)485 cited
- → Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab